Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial-Reference-Cited by-同舟云学术

Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial

Published:2016 Issue:2 Volume:1 Page:e000041
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Siena Salvatore,Tabernero Josep,Bodoky Gyorgy,Cunningham David,Rivera Fernando,Ruff Paul,Canon JeanLuc,Koukakis Reija,Demonty Gaston,Hechmati Guy,Douillard Jean-Yves

Funder

Amgen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?;Boyd;Trials,2011

2. Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: literature review and consensus;Russi;Crit Rev Oncol Hematol,2015

3. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment;Van Cutsem;Ann Oncol,2010

4. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS);Cherny;Ann Oncol,2015

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation;American Society of Clinical Oncology Educational Book;2024-06

3. Role of Patient-Reported Outcomes in Clinical Trials in Metastatic Colorectal Cancer: A Scoping Review;Cancers;2023-02-10

4. Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial;BMC Cancer;2022-06-28